KRAS mutations in pancreatic cancer cells rely on both endogenous TNF-related apoptosis-inducing ligands (TRAILs) as well as their receptors to promote tumor growth and metastasis (von Karstedt and Walczak, 2020). This evidence concerns the gene KRAS and familial pancreatic carcinoma.